Nephrology

Nephrology Nephrology is the branch of internal medicine that deals with the kidneys: how they filter blood, balance water and salts, regulate acid and blood pressure, and signal to the bone marrow and skeleton; and what happens when they fail.

10 frameworks, from 1827 to today · Internal Medicine · Medicine & Health

still a working view ended · each leads to its entry below

Overview

Nephrology

Nephrology is the branch of internal medicine that deals with the kidneys: how they filter blood, balance water and salts, regulate acid and blood pressure, and signal to the bone marrow and skeleton; and what happens when they fail. The stakes are unusually high for a small pair of organs. Untreated kidney failure is fatal within weeks, and the treatments that keep people alive without working kidneys—dialysis and transplantation—are among the most demanding and expensive in medicine. The field's history is largely the story of three problems: understanding what the kidney actually does, learning to see kidney disease in tissue and in numbers, and building machines and immune strategies that can stand in for, or replace, a failed organ.

The Kidney as a Filter: Physiology and Clearance

Nineteenth-century anatomy had already mapped the kidney's architecture—the glomerulus (the tuft of capillaries where blood is filtered), the tubules, and the looped structures named for their describer—but the organ's purpose was contested. Some held that the kidney secreted urine the way a gland secretes saliva; others that it filtered blood under pressure. The Scottish physician William Bowman described the capsule at the start of the glomerulus in 1842, and the German anatomist Carl Ludwig argued in the 1840s for a filtration–reabsorption model: water and small solutes are forced through the glomerular wall, and the tubules take back what the body needs. The competing secretory view was not fully displaced until the twentieth century.

The decisive tool was clearance. Clearance is the volume of blood plasma completely cleared of a substance per unit time; if a substance is filtered freely and neither reabsorbed nor secreted, its clearance measures the filtration rate. In the 1920s and 1930s, the American physiologist Homer Smith and colleagues used inulin—a plant carbohydrate filtered freely and handled by the kidney in exactly that way—to measure glomerular filtration rate (GFR) in humans. Clearance gave the kidney a measurable number, and with it a way to stage disease. The Danish physiologist Poul Brandt Rehberg had earlier used creatinine, a muscle waste product, for the same purpose; creatinine clearance remains the everyday clinical proxy because it needs only a blood and urine sample. The later refinement—estimating GFR from a blood creatinine level plus age, sex, and other variables, without any urine collection—turned kidney function into a routine laboratory number.

Clinical Syndromes and the Birth of a Specialty

Before there were treatments, there were patterns. Nineteenth-century clinicians grouped kidney disease by what the patient looked like: dropsy (swelling from retained fluid), scanty or bloody urine, and the "Bright's disease" complex named after the English physician Richard Bright, who in the 1820s and 1830s linked dropsy and protein in the urine to diseased kidneys seen at autopsy. The French physician Pierre Rayer and others distinguished acute from chronic forms. By the early twentieth century, the field had a working vocabulary of syndromes—nephrotic syndrome (heavy protein loss in the urine, low blood albumin, swelling), nephritic syndrome (blood and protein in the urine with high blood pressure and declining function), acute kidney injury, and chronic kidney failure—that organized clinical care long before the mechanisms were understood. This syndromic approach was the specialty's first operating model: diagnose by pattern, treat the consequences (fluid overload, high potassium, acidosis), and hope the kidney recovered.

The Biopsy and the Classification of Glomerular Disease

The next turning point came from the microscope. Percutaneous kidney biopsy—passing a needle into the kidney to obtain tissue—was developed in the mid-twentieth century, with the Danish physician Poul Iversen and the American Robert Kark among the pioneers in the 1940s and 1950s. Once tissue could be obtained safely, immunofluorescence (using antibodies tagged with a fluorescent dye to show where immune proteins sit in the glomerulus) and electron microscopy added a molecular layer to what light microscopy showed. The result was a classification of glomerular disease built on what the tissue looked like and what was deposited in it: for example, the distinction between minimal change disease (normal-looking glomeruli on light microscopy, foot-process fusion on electron microscopy) and focal segmental glomerulosclerosis; the recognition of IgA nephropathy by the French pathologist Jean Berger in 1968; and the separation of membranous nephropathy, membranoproliferative patterns, and the vasculitic and lupus-associated glomerulonephritides. The biopsy made the diagnosis specific and, crucially, made treatment decisions—steroids, immunosuppressants—testable against a defined lesion rather than a clinical impression.

Immunology Enters the Clinic

The mid-twentieth century also brought the insight that many kidney diseases are immune-mediated. The demonstration that antibodies and immune complexes deposit in the glomerulus, and that some forms of nephritis follow streptococcal infection or accompany systemic lupus, reframed glomerulonephritis as an immunological problem. The discovery of anti-glomerular basement membrane antibodies in Goodpasture's disease (the name honors the American pathologist Ernest Goodpasture, who described the lung–kidney syndrome in 1919) and of antineutrophil cytoplasmic antibodies (ANCA) in the small-vessel vasculitides in the 1980s gave clinicians serological markers and, with them, the rationale for plasma exchange and cytotoxic therapy. The treatment of these diseases—high-dose steroids, cyclophosphamide, later rituximab—was borrowed from oncology and transplant immunology and refined by controlled trials.

Dialysis: From Artificial Kidney to Chronic Care

The first working artificial kidney was built by the Dutch physician Willem Kolff in the occupied Netherlands during the Second World War, using sausage casing as the membrane and a rotating drum; his first patient, in 1943, was treated for acute kidney failure. The device proved that urea and other wastes could be removed from blood outside the body. The problem it could not solve was access: repeated treatment required a way to reach the bloodstream again and again. In 1960 the American physicians Belding Scribner and Wayne Quinton devised the Scribner shunt, a plastic tube connecting an artery to a vein that could be cannulated repeatedly, and chronic hemodialysis became possible. The Seattle program that followed raised the defining ethical question of the era—who gets a scarce life-saving treatment—and the "God committee" that adjudicated access became a landmark in medical ethics. The later arteriovenous fistula, created surgically from the patient's own vessels, gave a more durable and less infection-prone access and remains the preferred route today.

Hemodialysis also became an operating model of care, not just a machine: outpatient units, fixed schedules (typically three sessions a week), vascular-access surgery, dialysis nursing, and the management of anemia, bone disease, and nutrition in people living for years on treatment. Peritoneal dialysis developed in parallel. The peritoneum, the membrane lining the abdominal cavity, can serve as the filtering membrane if dialysis fluid is instilled into the abdomen and drained; the German physician Georg Ganter attempted it in the 1920s, and the technique became practical in the 1960s and 1970s with the development of indwelling catheters (notably by the American physician Henry Tenckhoff) and sterile, bagged solutions. Peritoneal dialysis offered home treatment and preserved residual kidney function, and it became a major modality in many health systems, especially where hemodialysis capacity is limited.

Transplantation and the Control of Rejection

Kidney transplantation is the only treatment that restores full kidney function, and its history is the history of transplant immunology. Early attempts in the first decade of the twentieth century failed because the immune system destroyed the graft. The turning point was the recognition of the immune basis of rejection and the demonstration, by the British biologist Peter Medawar and colleagues in the 1940s and 1950s, that rejection is an immunological process that can be studied and, in principle, suppressed. The first successful kidney transplant between identical twins was performed by Joseph Murray in Boston in 1954, proving that a kidney could function in a new body if the immune barrier were absent1. The discovery of the human leukocyte antigen (HLA) system by Jean Dausset and others in the 1950s and 1960s made matching possible, and the drug azathioprine, used with steroids from the early 1960s, produced the first durable success with unrelated donors. Cyclosporine, introduced in the late 1970s and 1980s, was a genuine revolution: it suppressed T-cell activation selectively enough to prevent rejection without destroying the whole immune system, and it made transplantation a routine rather than experimental therapy. Modern immunosuppression—tacrolimus, mycophenolate, induction antibodies, and regimens tailored to individual risk—descends directly from that line, and the field's persistent problems (chronic graft loss, infection, cancer, and the shortage of organs) are its open questions.

Counting Kidney Disease: Staging and Epidemiology

As dialysis and transplantation became available, medicine needed a way to identify who would need them and when. The answer was a staging system built on GFR. In 2002 the Kidney Disease Outcomes Quality Initiative (KDOQI) of the US National Kidney Foundation published a classification of chronic kidney disease (CKD) into stages 1–5 based on estimated GFR and evidence of kidney damage, with stage 5 corresponding to the threshold for renal replacement therapy. The system was refined and internationally adopted (notably by KDIGO, the Kidney Disease: Improving Global Outcomes initiative) with the addition of albuminuria categories, because protein in the urine predicts progression independently of GFR. Staging did something no previous framework had done: it defined CKD as a population-level condition, not just a set of individual diagnoses, and made it measurable in large cohorts. Epidemiology followed—studies such as the US NHANES surveys and international collaborations established that CKD is common, often unrecognized, and strongly associated with cardiovascular death. The modern understanding that most people with CKD die of cardiovascular disease before reaching dialysis reframed the field's priorities toward early detection, blood-pressure control, and organ-protective drugs.

The Present

Contemporary nephrology rests on all of these foundations at once. Clinical care is organized around estimated GFR and albuminuria staging, biopsy-based diagnosis of glomerular disease, and syndrome-driven management of electrolytes and acid–base disorders—the everyday work of correcting potassium, sodium, and pH that has been the internist's craft since the nineteenth century but is now guided by physiology and measured outcomes. Dialysis is a mature industry with unresolved questions about dose, timing, and patient-reported outcomes; peritoneal dialysis is being re-expanded as a home therapy; and transplantation is limited chiefly by organ supply, with xenotransplantation and machine perfusion under active investigation. The most consequential recent shift is pharmacological: drugs that slow CKD progression by protecting the kidney directly—ACE inhibitors and angiotensin-receptor blockers from the 1990s, SGLT2 inhibitors repurposed from diabetes in the 2010s, and newer agents such as finerenone—have made "slowing progression" a realistic clinical goal rather than a hope. What remains open is the deepest problem the field has carried since Bright: most chronic kidney disease is silent until late, its earliest mechanisms are incompletely understood, and the therapies that work are still unevenly delivered.

References

  1. Kidney transplantation (introduction, History), Wikipedia

The frameworks of Nephrology

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1827-Present

    Clinical Syndromic Diagnosis

    What pattern of signs defines this kidney disease?

    Fly to its tower in Nousfarer

  2. 1840-Present
  3. 1943-Present

    Hemodialysis as Chronic Care

    How can a machine replace kidney function long term?

    Fly to its tower in Nousfarer

  4. 1950-Present
  5. 1950-Present

    Immune-Mediated Glomerulonephritis

    How does immune attack damage the glomerulus?

    Fly to its tower in Nousfarer

  6. 1950-Present

    Renal Pathology and Biopsy-Based Classification

    What does kidney tissue look like under the microscope?

    Fly to its tower in Nousfarer

  7. 1954-Present

    Transplant Immunology and Immunosuppression

    How can a transplanted organ escape immune rejection?

    Fly to its tower in Nousfarer

  8. 1960-Present

    Peritoneal Dialysis

    Can the abdominal lining serve as a dialysis membrane?

    Fly to its tower in Nousfarer

  9. 1990-Present

    Organ-Protective Pharmacotherapy

    Which drugs slow the loss of kidney function?

    Fly to its tower in Nousfarer

  10. 2002-Present

    CKD Staging and Epidemiology

    How severe is this patient's chronic kidney disease?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Clinical Syndromic DiagnosisFiltration–Reabsorption PhysiologyHemodialysis as Chronic CareElectrolyte and Acid–Base Physiology …Immune-Mediated GlomerulonephritisRenal Pathology and Biopsy-Based Clas…Transplant Immunology and Immunosuppr…Peritoneal DialysisOrgan-Protective PharmacotherapyCKD Staging and Epidemiology

Beyond the field

Where Nephrology's ideas came from in other fields, and what they led to there: the strongest 12 of 28 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Nephrology is a planet in Nousfarer

Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.

Land on Nephrology

Related fields

Fields its ideas are linked to

More in Internal Medicine

See where Nephrology sits on the Map of Human Knowledge